NKTX / Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus Drug

Nkarta (NKTX) rallies 112% on FDA nod to begin the clinical development of its investigational candidate, NKX019, for the treatment of lupus nephritis more_horizontal

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural more_horizontal

Nkarta, Inc. (NKTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement amo more_horizontal

Nkarta's lead therapy showed limited effectiveness in treating acute myeloid leukemia. Last week, there was a rash of insider selling by company execu more_horizontal

SOUTH SAN FRANCISCO, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural more_horizontal

SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural more_horizontal

Biotech stock fortunes hinge upon potential, progress, and the ultimate realization of drugs and devices that treat diseases. Stringent regulatory pro more_horizontal

NKTX has consistently produced solid data from its NK cell programs. Despite that, the stock is going down. more_horizontal